市场快照

Study Period: | 2018 - 2026 |
Base Year: | 2021 |
CAGR: | 5.9 % |
![]() |
Need a report that reflects how COVID-19 has impacted this market and its growth?
市场概况
老年人口的增加可能会导致亚太地区对手术的需求显着增加。手术数量的整体增加对亚太地区的麻醉药物市场产生了强烈影响,因为麻醉药物用于外科手术以减轻疼痛。老年人群极易患退行性疾病和慢性疾病,这导致手术和治疗的边缘增加。这需要持续监测,因此有望推动麻醉药物市场的增长。
增加对市场的投资,支持麻醉药物和管理的研发,正在对市场增长产生重大影响,从而加快在医疗保健行业的部署。
报告范围
麻醉是一种导致可逆性感觉丧失的药物。市场上有几种麻醉药物可供选择,例如全身麻醉、脊髓麻醉、IV 区域麻醉、局部麻醉、周围神经阻滞和鞍座阻滞或尾部麻醉。
By Drug Type | ||||||||||
| ||||||||||
|
By Route of Administration | |
Inhalation | |
Injection | |
Other Routes of Administration |
By Application | |
General Surgery | |
Plastic Surgery | |
Cosmetic Surgeries | |
Dental Surgeries | |
Other Applications |
Geography | ||||||||
|
主要市场趋势
普外科应用有望主导市场
在手术期间,给予某种形式的麻醉以减轻疼痛和感觉。对于小型手术,可以通过注射到该部位给予局部麻醉剂或让其吸收到皮肤中。区域麻醉仅用于麻木将接受手术的身体部分。通常,在为身体该部位提供感觉的神经区域注射局部麻醉剂。
根据 Jin Xu 等人在 BMJ 杂志上发表的 2019 年文章,亚太地区的医院继续快速扩张。从 2008 年到 2017 年,医院就诊人数增加了 93.1%,而初级保健机构增加了 49.5%。从 2008 年到 2017 年,住院人数增加了 2.4 倍(平均每年 10%)。入院人数的增加导致对手术麻醉药物的需求增加,这有助于亚太地区这一市场的增长。

To understand key trends, Download Sample Report
竞争格局
亚太地区大部分国家都是发展中国家。这些发展中经济体有大量无人看管的疾病和受伤的人可以在医院接受治疗。因此,这些国家在麻醉药物方面具有很高的潜力,因此对于全球参与者进入市场来说是非常有利可图的。因此,该地区拥有市场上大多数全球参与者的存在。此外,还有一些区域参与者也在该地区建立了自己的存在。
Table of Contents
-
1. INTRODUCTION
-
1.1 Study Deliverables
-
1.2 Study Assumptions
-
1.3 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Increasing Geriatric Population and a Rise in the Number of Surgical Procedures Requiring Anesthesia
-
4.2.2 Large Patient Pool Due to Chronic Diseases
-
4.2.3 New Anesthesia Product Approvals
-
-
4.3 Market Restraints
-
4.3.1 Side Effects of General Anesthetics
-
4.3.2 Regulatory Issues
-
-
4.4 Porter's Five Forces Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Drug Type
-
5.1.1 General Anesthesia Drugs
-
5.1.1.1 Propofol
-
5.1.1.2 Sevoflurane
-
5.1.1.3 Desflurane
-
5.1.1.4 Isoflurane
-
5.1.1.5 Dexmedetomidine
-
5.1.1.6 Remifentanil
-
5.1.1.7 Midazolam
-
5.1.1.8 Other General Anesthesia Drugs
-
-
5.1.2 Local Anesthesia Drugs
-
5.1.2.1 Bupivacaine
-
5.1.2.2 Ropivacaine
-
5.1.2.3 Lidocaine
-
5.1.2.4 Chloroprocaine
-
5.1.2.5 Articaine
-
5.1.2.6 Benzocaine
-
5.1.2.7 Other Local Anesthesia Drugs
-
-
-
5.2 By Route of Administration
-
5.2.1 Inhalation
-
5.2.2 Injection
-
5.2.3 Other Routes of Administration
-
-
5.3 By Application
-
5.3.1 General Surgery
-
5.3.2 Plastic Surgery
-
5.3.3 Cosmetic Surgeries
-
5.3.4 Dental Surgeries
-
5.3.5 Other Applications
-
-
5.4 Geography
-
5.4.1 Asia-Pacific
-
5.4.1.1 China
-
5.4.1.2 Japan
-
5.4.1.3 India
-
5.4.1.4 Australia
-
5.4.1.5 South Korea
-
5.4.1.6 Rest of Asia-Pacific
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 AbbVie Inc.
-
6.1.2 Aspen Holdings
-
6.1.3 Baxter International
-
6.1.4 B. Braun Melsungen AG
-
6.1.5 Eisai Co. Ltd
-
6.1.6 F. Hoffmann-La Roche AG
-
6.1.7 Fresenius SE & Co. KGaA
-
6.1.8 Novartis AG (Sandoz)
-
6.1.9 Piramal Enterprises Limited
-
*List Not Exhaustive -
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Asia-Pacific Anesthesia Drugs Market market is studied from 2018 - 2026.
What is the growth rate of Asia-Pacific Anesthesia Drugs Market?
The Asia-Pacific Anesthesia Drugs Market is growing at a CAGR of 5.9% over the next 5 years.
Who are the key players in Asia-Pacific Anesthesia Drugs Market?
AbbVie Inc, Aspen Holdings, Baxter International, Fresenius SE & Co. KGaA, B. Braun Melsungen AG are the major companies operating in Asia-Pacific Anesthesia Drugs Market.